Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation

Creative Commons License

DE LA MORENA M. T. , LEONARD D., Torgerson T. R. , CABRAL-MARQUES O., SLATTER M., AGHAMOHAMMADI A., ...More

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol.139, no.4, pp.1282-1292, 2017 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 139 Issue: 4
  • Publication Date: 2017
  • Doi Number: 10.1016/j.jaci.2016.07.039
  • Title of Journal : JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
  • Page Numbers: pp.1282-1292

Abstract

Background: X-linked hyper-IgM syndrome (XHIGM) is a primary immunodeficiency with high morbidity and mortality compared with those seen in healthy subjects. Hematopoietic cell transplantation (HCT) has been considered a curative therapy, but the procedure has inherent complications and might not be available for all patients.